Cargando…
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial was set up in March 2020 to evaluate treatments for people hospitalised with COVID-19. To maximise recruitment it was designed to fit into routine clinical care throughout the UK, and as a result it has enrolled more patients than any ot...
Autores principales: | Peto, Leon, Horby, Peter, Landray, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293394/ https://www.ncbi.nlm.nih.gov/pubmed/35915043 http://dx.doi.org/10.1016/j.jbior.2022.100901 |
Ejemplares similares
-
Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021) -
Randomised controlled trials for mpox in endemic countries
por: Rojek, Amanda, et al.
Publicado: (2023) -
Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
por: Águas, Ricardo, et al.
Publicado: (2021) -
Author Correction: Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
por: Águas, Ricardo, et al.
Publicado: (2021) -
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
por: Landray, M.J., et al.
Publicado: (2017)